Gold bars to be exempt from tariffs, White House clarifies
Investing.com - UBS lowered its price target on Zoetis Inc . (NYSE:ZTS) to $165 from $170 while maintaining a Neutral rating following the animal health company’s second-quarter financial results. The stock currently trades near its 52-week low of $139.70, with broader analyst targets ranging from $153 to $230.
The firm described Zoetis’s quarterly performance as "mixed but not necessarily thesis-changing," according to a research note published this week. InvestingPro data shows the company maintains a GOOD financial health score, with revenue growing 6.32% over the last twelve months.
UBS highlighted that stability in U.S. dermatology results will become an increasingly important focal point for investors ahead of anticipated competition in this segment.
The investment bank expressed concern that investors will need "greater reassurance" that Zoetis can sustain its top-line outlook until new innovation helps reinvigorate revenue growth.
UBS sees "limited prospects for multiple expansion in the near-term," particularly ahead of what it describes as "challenging optics" expected in the third quarter, supporting its decision to maintain a Neutral stance on the stock.
In other recent news, Zoetis Inc. reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $1.76, compared to the forecasted $1.62. Zoetis also exceeded revenue projections, reaching $2.46 billion against an anticipated $2.41 billion. These results highlight the company’s strong performance in the recent quarter. Analysts had projected lower figures, indicating that Zoetis outperformed market expectations. The positive earnings report reflects robust business operations and financial health. Investors showed confidence in the company’s results, as evidenced by the market’s reaction following the announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.